Literature DB >> 6417155

Age-related changes in plasma growth hormone response to growth hormone-releasing factor in man.

T Shibasaki, K Shizume, M Nakahara, A Masuda, K Jibiki, H Demura, I Wakabayashi, N Ling.   

Abstract

The response of plasma growth hormone to synthetic growth hormone-releasing factor (hpGRF-44) administered intravenously was examined in normal men of various ages ranging from 20 to 75 years. Most of the subjects who were over forty years old had either no or much lower response of plasma growth hormone to hpGRF-44. In contrast plasma growth hormone increased markedly after hpGRF-44 injection in all men in their twenties and thirties. The mean peak level of plasma GH following hpGRF-44 administration was 29.6 +/- 20.4 (SD) ng/ml in men in their twenties, 30.2 +/- 26.5 ng/ml in their thirties, 9.7 +/- 5.2 ng/ml in their forties, 10.9 +/- 5.4 ng/ml in their fifties, 8.4 +/- 4.8 ng/ml in their sixties and 8.1 +/- 7.5 ng/ml in their seventies. These results suggest that somatotroph cells become less sensitive to growth hormone-releasing factor with aging.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6417155     DOI: 10.1210/jcem-58-1-212

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors.

Authors:  A Colao; G Cerbone; R Pivonello; M Klain; G Aimaretti; A Faggiano; C Di Somma; M Salvatore; G Lombardi
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

2.  Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Chandra Inglis; Anthony Adame; Christina Patrick; Kristen Whitney; Eliezer Masliah
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 3.  Hormonal alterations due to exercise.

Authors:  J C Bunt
Journal:  Sports Med       Date:  1986 Sep-Oct       Impact factor: 11.136

4.  Human pancreatic growth hormone-releasing factor (hpGRF-44) in acromegaly before and after adenomectomy. Modifications induced by somatostatin (GHRIH) infusion.

Authors:  M Arosio; B Ambrosi; L Guglielmino; G Faglia
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

5.  Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

Authors:  E Mazza; E Ghigo; S Goffi; M Procopio; E Imperiale; E Arvat; J Bellone; M F Boghen; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

6.  Impaired growth hormone response to human pancreatic growth hormone releasing factor [GRF(1-44)] in type 2 (non-insulin-dependent) diabetes.

Authors:  N T Richards; S M Wood; N D Christofides; S C Bhuttacharji; S R Bloom
Journal:  Diabetologia       Date:  1984-11       Impact factor: 10.122

7.  The effect of genetic variability (degree of homozygosity) on serum levels of the anterior pituitary hormones prolactin, corticotropin, and growth hormone in rats.

Authors:  B Kosowska
Journal:  Biochem Genet       Date:  1992-12       Impact factor: 1.890

8.  A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.

Authors:  E Ghigo; S Goffi; E Arvat; E Imperiale; G M Boffano; M R Valetto; E Mazza; I Santi; A Magliona; M F Boghen
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

9.  Study on the mechanism of abnormal growth hormone (GH) secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion.

Authors:  A Masuda; T Shibasaki; M Hotta; H Suematsu; K Shizume
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

10.  Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency.

Authors:  M B Ranke; M Gruhler; R Rosskamp; G Brügmann; A Attanasio; W F Blum; J R Bierich
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.